Teva: This One Is Difficult (NYSE:TEVA) | Seeking Alpha
S&P: Teva faces greatest liability in US antitrust suit - Globes
Teva Pharmaceutical (TEVA)
The Possible Reason why Teva (NYSE:TEVA) is Still Trading Below Intrinsic Value - Simply Wall St News
Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal
Teva Pharmaceutical Stock: Prepare For Takeoff (NYSE:TEVA) | Seeking Alpha
Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024
Teva woes deepen as Fitch cuts credit rating to junk | The Times of Israel
Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early Settlement - FactEntry
Credit Trends: Downgrade Potential Spikes In Latin America | S&P Global Ratings
Teva Bonds: 8.8% Yield To Maturity Understates Upside (NYSE:TEVA) | Seeking Alpha
Teva Bonds: 8.8% Yield To Maturity Understates Upside | Nasdaq
Teva pharmaceutical industries - Pharma
Fitch downgrades Teva debt - Globes
Teva Bonds: 8.8% Yield To Maturity Understates Upside (NYSE:TEVA) | Seeking Alpha
Moody's upgrades Teva's rating outlook - Globes
S&P downgrades Teva, pushing credit rating further into junk territory - Business - Haaretz.com
Credit Rating Process | A Complete Beginner's Guide
Teva woes deepen as Fitch cuts credit rating to junk | The Times of Israel
Credit Rating Process | A Complete Beginner's Guide
Teva eases debt burden with $400M tender offer as turnaround effort escalates | Fierce Pharma
Teva Faces Rocky Path to Recovery After Debt | Fortune
Teva Pharmaceuticals Ratings Cut at Fitch - TheStreet
S&P cuts Teva's rating on rising litigation risks
Teva May Have to Make Difficult Capital Allocation Decisions Under Pressure From Potential Generic Competition, Deleveraging Goals - Reorg
Teva Pharmaceutical Industries. Information about the issuer. (LEI 549300BAFGM4RC74ZJ94, SWIFT TEVPILITXXX). News and credit ratings. Tables with accounting and financial reports.
Teva: The Road To Perdition Has Turned Into A Path Towards Redemption (NYSE: TEVA) | Seeking Alpha
